OLD National Bancorp IN Has $3.85 Million Stake in Quest Diagnostics Incorporated $DGX

OLD National Bancorp IN trimmed its holdings in shares of Quest Diagnostics Incorporated (NYSE:DGX) by 12.5% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 22,168 shares of the medical research company’s stock after selling 3,181 shares during the quarter. OLD National Bancorp IN’s holdings in Quest Diagnostics were worth $3,847,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. JFS Wealth Advisors LLC increased its position in Quest Diagnostics by 114.3% during the fourth quarter. JFS Wealth Advisors LLC now owns 150 shares of the medical research company’s stock worth $26,000 after buying an additional 80 shares during the last quarter. True Wealth Design LLC increased its position in Quest Diagnostics by 369.7% during the third quarter. True Wealth Design LLC now owns 155 shares of the medical research company’s stock worth $30,000 after buying an additional 122 shares during the last quarter. Harbor Investment Advisory LLC increased its position in Quest Diagnostics by 113.7% during the fourth quarter. Harbor Investment Advisory LLC now owns 156 shares of the medical research company’s stock worth $27,000 after buying an additional 83 shares during the last quarter. First Horizon Corp acquired a new position in Quest Diagnostics during the third quarter worth $33,000. Finally, Caitong International Asset Management Co. Ltd acquired a new position in Quest Diagnostics during the third quarter worth $33,000. 88.06% of the stock is owned by institutional investors and hedge funds.

Quest Diagnostics Stock Performance

NYSE:DGX opened at $199.15 on Friday. Quest Diagnostics Incorporated has a 1 year low of $164.65 and a 1 year high of $213.50. The firm’s fifty day simple moving average is $200.26 and its 200 day simple moving average is $189.19. The company has a current ratio of 1.18, a quick ratio of 0.96 and a debt-to-equity ratio of 0.67. The firm has a market capitalization of $22.04 billion, a PE ratio of 22.01, a PEG ratio of 2.61 and a beta of 0.66.

Quest Diagnostics (NYSE:DGX) last posted its earnings results on Tuesday, April 21st. The medical research company reported $2.50 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.37 by $0.13. The business had revenue of $2.90 billion for the quarter, compared to analyst estimates of $2.83 billion. Quest Diagnostics had a net margin of 9.07% and a return on equity of 15.60%. Quest Diagnostics’s revenue was up 9.2% compared to the same quarter last year. During the same period last year, the business posted $1.94 EPS. Quest Diagnostics has set its FY 2026 guidance at 10.630-10.830 EPS. On average, sell-side analysts anticipate that Quest Diagnostics Incorporated will post 10.69 EPS for the current year.

Quest Diagnostics Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, April 20th. Shareholders of record on Monday, April 6th were given a $0.86 dividend. The ex-dividend date was Monday, April 6th. This represents a $3.44 annualized dividend and a yield of 1.7%. This is a positive change from Quest Diagnostics’s previous quarterly dividend of $0.80. Quest Diagnostics’s dividend payout ratio (DPR) is 38.01%.

Quest Diagnostics announced that its board has initiated a stock repurchase program on Tuesday, February 10th that authorizes the company to repurchase $1.00 billion in outstanding shares. This repurchase authorization authorizes the medical research company to purchase up to 4.7% of its stock through open market purchases. Stock repurchase programs are generally a sign that the company’s board of directors believes its stock is undervalued.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on DGX shares. Wall Street Zen lowered shares of Quest Diagnostics from a “buy” rating to a “hold” rating in a research note on Sunday, March 15th. Citigroup raised their target price on shares of Quest Diagnostics from $190.00 to $215.00 and gave the company a “neutral” rating in a research note on Tuesday, February 10th. UBS Group raised their target price on shares of Quest Diagnostics from $210.00 to $220.00 and gave the company a “neutral” rating in a research note on Wednesday. Jefferies Financial Group reiterated a “buy” rating and issued a $225.00 target price on shares of Quest Diagnostics in a research note on Tuesday. Finally, Weiss Ratings reiterated a “buy (b-)” rating on shares of Quest Diagnostics in a research note on Monday, December 29th. Seven equities research analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $214.54.

Key Stories Impacting Quest Diagnostics

Here are the key news stories impacting Quest Diagnostics this week:

• Positive Sentiment: Q1 beat and raised FY‑2026 outlook — Quest reported stronger-than-expected Q1 revenue and EPS and raised its 2026 guidance, with the CEO citing broad‑based growth across consumer testing and advanced diagnostics. That fundamental beat is the primary bullish catalyst. Quest Diagnostics raises 2026 forecast, CEO highlights broad‑based growth
• Positive Sentiment: Analysts raised estimates and price targets after Q1 — Several firms lifted forecasts/targets (UBS, Robert W. Baird, Barclays, Truist) and coverage pieces highlighted upgraded revenue/earnings outlooks, supporting upside to consensus. These Analysts Boost Their Forecasts On Quest Diagnostics After Better-Than-Expected Earnings
• Positive Sentiment: Technical/market‑strength signal — IBD upgraded Quest for improved price strength, which can attract momentum and retail flows. IBD rating upgrades: Quest Diagnostics shows improved price strength
• Positive Sentiment: Zacks/style momentum coverage — Commentary suggesting DGX is a momentum stock may reinforce interest from style‑focused funds. Here’s Why Quest Diagnostics (DGX) is a Strong Momentum Stock
• Neutral Sentiment: Earnings call / deep dive pieces — Multiple writeups summarize the call and the shifting investment story (organic growth, consumer testing momentum, advanced diagnostics). Useful for longer‑term thesis but less likely to move the tape intraday. Quest Diagnostics Inc (DGX) Q1 2026 Earnings Call Highlights DGX Q1 deep dive
• Negative Sentiment: Hedge fund short call — Hedgeye added DGX as a new short idea, creating headline risk and giving short sellers a narrative to increase pressure in the near term. That can amplify intraday selling even with positive fundamentals. Quest Diagnostics added as new short idea at Hedgeye

Insider Activity at Quest Diagnostics

In other Quest Diagnostics news, SVP Karthik Kuppusamy sold 2,628 shares of the firm’s stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $204.86, for a total value of $538,372.08. Following the sale, the senior vice president directly owned 13,441 shares in the company, valued at $2,753,523.26. This trade represents a 16.35% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Michael E. Prevoznik sold 3,878 shares of the firm’s stock in a transaction on Thursday, March 5th. The stock was sold at an average price of $206.21, for a total transaction of $799,682.38. Following the completion of the sale, the senior vice president owned 37,557 shares in the company, valued at $7,744,628.97. This represents a 9.36% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 24,083 shares of company stock valued at $4,945,262. Company insiders own 8.16% of the company’s stock.

Quest Diagnostics Company Profile

Quest Diagnostics (NYSE: DGX) is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening.

Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology.